Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
5386987
Reference Type
Book/Book Chapter
Title
Perfluorohexanoic acid pharmacokinetics in mouse, rat, microminipig, pig, monkey and human
Author(s)
Buck, R; Gannon, S
Year
2017
Is Peer Reviewed?
0
Journal
Abstracts of Papers of the American Chemical Society
ISSN:
0065-7727
Publisher
American Chemical Society
Location
Washington, DC
Book Title
Abstracts of Papers of the 253rd National meeting of the American Chemical Society
Volume
253
Language
English
Web of Science Id
WOS:000430569101450
Abstract
Perfluorohexanoic acid (PFHxA) is a perfluorocarboxylic acid (PFCA) that has been widely identified in the aqueous environment. In order to conduct a human health risk characterization, it is necessary to understand both its toxicology and phamacokinetics in mammals. The elimination kinetics of PFHxA have been determined from published data for multiple mammalian species: mouse, rat, microminipig, pig, monkey and human. For each species, the data was compiled and modeled to identify the kinetic profile of elimination from blood including calculation of elimination rate (hr-1) and elimination half-life (hr). The study shows that PFHxA elimination kinetics in mammals is consistent with a rapid initial (alpha) phase followed by a slower terminal (beta) phase. Further, the PFHxA alpha phase elimination has a first-order half-life range of 1-2 hours in mouse, rat, microminipig, pig, monkey and human. The alpha phase elimination in mammals accounts for over 99.7% of the total PFHxA elimination in mammals. PFHx- elimination is extensive in the rapid alpha phase and there are no significant pharmacokinetic differences across mammals: mice, rats, monkeys, pigs and humans. The overall conclusion of this kinetic assessment is that PFHxA does not appear to exhibit significantly different elimination kinetics across a wide range of mammalian species. The results suggest that for human health risk assessment, the interspecies pharmacokinetics adjustment factor applied to a hazard assessment benchmark should be small. Details of the assessment for each species will be presented.
ISBN
9780841232044
Conference Name
253rd National Meeting of the American-Chemical-Society (ACS) on Advanced Materials, Technologies, Systems, and Processes
Conference Location
San Francisco, CA
Conference Dates
April 2-6, 2017
Tags
PFAS
•
Additional PFAS (formerly XAgency)
•
PFAS 150
Literature Search Update December 2020
WOS
Literature Search August 2019
Web of Science
Not prioritized for screening
Perfluorohexanoic acid
1,1,1,3,3,3-Hexafluoro-2- (fluoromethoxy)propane
•
PFHxA
Title and Abstract Screening
Tagged as Supplemental
ADME TK
HAWC
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity